Senti Biosciences Holdings, Inc.
Close on Oct 19, 2026
- Market cap
- $7.06M
- P/E (TTM)
- –
- Dividend yield
- –
About Senti Biosciences
Biological Products, (No Diagnostic Substances), SIC 2836
Senti Biosciences is a clinical-stage biotechnology company that develops cell and gene therapies using synthetic biology and proprietary gene circuit technologies. The company programs cells with biological logic to target and destroy cancer cells while sparing healthy tissue. Its lead product candidate is SENTI-202, an off-the-shelf chimeric antigen receptor natural killer cell therapy designed to treat relapsed or refractory hematological malignancies, including acute myeloid leukemia. In addition to internal oncology initiatives, Senti Biosciences maintains preclinical programs in solid tumors and partners with BlueRock Therapeutics to develop cell therapies for regenerative medicines.
The company conducts clinical trials in the United States and Australia. Senti Biosciences has its contract clinical manufacturing performed in Alameda, California, following the sale of manufacturing assets and sublease of its facility to GeneFab. The company holds worldwide licensing agreements with the National Cancer Institute for chimeric antigen receptor technologies.
Summary of the business section of Senti Biosciences's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Senti Biosciences Holdings, Inc.
- Headquarters
- South San Francisco, CA
- Address
- 2 Corporate Drive, First Floor 94080
- Phone
- (650) 239-2030
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, San Francisco, CA,
Stock & identifiers
- Ticker
- SNTI
- Exchange
- Nasdaq
- Shares outstanding
- 31M, Jul 31, 2026
- Public float
- $53.20M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-10 reverse, Jul 18, 2024; 1-for-10 reverse, Jul 17, 2024; 1-for-10 reverse, Aug 15, 2022
- SEC CIK
- 1854270
- CUSIP
- 816944102
- ISIN
- US8169441024
- EIN
- 86-2437900
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Timothy K. Lu | CEO, Director | 745,261 |
| Kanya Rajangam | Pres. & Chief Med. & Dev. Off. | 107,843 |
| John Harry Cross III | Chief Financial Officer | – |
| Bryan Daniel Baum | Director | – |
| Donald F. Tang | Director | 10,368 |
| Edward T. Mathers | Director | – |
| James J. Collins | Director | 176,130 |
| Fran Schulz | Director | – |
| Brenda Cooperstone | Director | – |
| Feng Hsiung | Director | – |
Corporate history
Events identified from SEC filings